First iPS cell basic patent application was filed in Japan, based on which its corresponding international application (PCT application) was filed in the following year.
Professor Shinya Yamanaka’s group reported the establishment of mouse iPS cells by introducing 4 factors, Oct3/4, Sox2, Klf4 and c-Myc, into mouse skin cells in the journal “Cell.”
Professor Shinya Yamanaka’s group reported the establishment of human iPS cells by introducing 4 factors,Oct3/4, Sox2, Klf4 and c-Myc, into human skin cells in the journal “Cell.” Professor James Thomson’s group also reported human iPS cells established with a different method in another journal on the same day
iPS Academia Japan, Inc. was established in Kyoto on June 25, 2008 to promote the transfer of iPS cell-related technologies to industry for its commercialization. We started as an affiliate of Kyoto University with a mission to share the fruit of iPS cell research for the good of all humanity.
The world's first iPS cell basic patent was granted in Japan. So far, 8 basic patents (our ref.: AJ001) have been granted in Japan. Further, their corresponding patents have been granted in more than 30 countries and regions worldwide.
Our first license agreement was entered into with ReproCELL, Inc. Since then, our licensees have gradually increased year by year.
Our first overseas license agreement was entered into with Cellular Dynamics International, Inc. (currently Fujifilm Cellular Dynamics, Inc.). iPS cell technology raised interest not only in Japan where iPS cells were invented, but also in countries where more ES cell research was conducted, which, as a result, increased foreign licensees.
The patents of iPierian, Inc. were assigned to Kyoto University to avoid a potential patent dispute in the U.S.A. In return, we granted to iPierian a license under Kyoto University’s basic patents and the former iPierian patents.
Professor Shinya Yamanaka and Sir John B. Gurdon were jointly awarded the Nobel Prize in Physiology or Medicine for the discovery that mature cells could be reprogrammed to become pluripotent.
Increasing numbers of patents were licensed not only from Kyoto University but from other universities and research institutions. The patents related to applications such as differentiation methods began to increase.
A part of our business was transferred to iPS Portal, Inc. Our business previously included research, sales of cells, etc., but since then, we have been specializing in patent licensing.
We were relocated to a new building in Yoshida Campus of Kyoto University.
We became an approved TLO in Japan by the authorization of both the Minister of Education, Culture, Sports, Science and Technology (MEXT), and the Minister of Economy, Trade and Industry (METI).
We handled more patents from our licensors, and total 500 patents became available for licensing.
The year 2018 marks the 10th anniversary of our company foundation. As of June, 2018, we have about 110 domestic licensees and 70 foreign licensees, and have licenses from Kyoto University and 14 other universities and research institutions.
We deeply appreciate your interest in iPS cell-related patents and your understanding to our patent licensing operation. In order to boost the industrialization of technology related to pluripotent stem cells including iPS cells, we will continue our efforts, therefore, we are highly appreciated of all your feedback and support for our activities.